Abstract:ObjectivesThe CRISPR-Cas system (clustered regularly interspaced short palindromic repeats and CRISPR associated genes) has emerged as a programmable and versatile tool for precise genome editing. The specificity of the CRISPR-Cas9 system is dictated by a 20-nucleiotide CRISPR guide RNA. The Cas9 protein is a double-stranded DNA nuclease guided by guide RNA to sequence-specific sites. The interaction between the Cas9 protein and the target DNA sequences leads to lethal cleavage of double-stranded DNA. Objectives of this study were to design and clone a guide RNA targeting Shiga toxin in pCRISPR and use a 2-plasmid platform to deliver this Shiga toxin specific CRISPR-Cas9 system into bacterial cells for specific killing of Shiga toxin-producing Escherichia coli. Materials and MethodsThe E. coli O157:H7 cells containing pCRISPR were cultured on tryptic soy agar (TSA) with 50 µg/ml of kanamycin, cells containing pCas9 were cultured on TSA with 50 µg/ml of chloramphenicol, and those containing both pCRISPR and pCas9 plasmids were cultured on TSA with 50 µg/ml of kanamycin and 50 µg/ml of chloramphenicol. Shiga toxin guide RNA was designed by screening Shiga toxin gene sequences for NGG on the 3’ side. The pCRISPR vector was digested with BsaI (10 units) and purified using a Monarch gel extraction kit (New England Biolabs). The designed guide RNA was ligated with the digested pCRISPR to create a new plasmid of pCRISPR w/stx. After ligation, the cloned region was sequenced by a Sanger Sequencing service (Genewiz). The pCas9 and pCRISPR w/stx were introduced into E. coli O157:H7 cells sequentially by electroporation: first the pCas9 was introduced into E. coli O157:H7 cells and then the pCRISPR w/stx was introduced into the recipient E. coli O157:H7 cells containing pCas9 plasmids. Briefly, E. coli O157:H7 cells were grown to a A₆₀₀ of 0.4 to 0.6. Plasmids (around 100 ng each) were transformed into bacterial cells using 0.1 cm Gene Pulser cuvettes (Bio-Rad) and the Electroporator 2510 (Eppendorf) set at 1800 V. In addition to pCRISPR w/stx, pCRISPR cloned with a piece of oligo that does not target any DNA sequences in E. coli O157:H7 cells (pCRISPR w/oligo) and the original pCRISPR were used as controls. After electroporation, cells were plated onto TSA plates containing appropriate antibiotics for quantification. ResultsSanger sequencing confirmed that the guide RNA targeting Shiga toxin genes was successfully cloned in pCRISPR. When the newly created pCRISPR w/stx plasmid was introduced into the recipient E. coli O157:H7 cells containing pCas9 plasmids, an approximately 2 log lower concentration of E. coli O157:H7 cells was observed compared to that of the control plasmids of pCRISPR w/oligo and pCRISPR (Table 1). ConclusionThis study provides proof-of-concept evidence that introduction of a CRISPR-Cas9 system that specifically cleaves Shiga toxin genes in bacterial cells leads to death of Shiga toxin-producing E. coli. The CRISPR-Cas system could be further explored for improving meat safety by sequence-specific removal of pathogens that harbor target virulence or antibiotic resistance genes.

Elimination of blaKPC−2-mediated carbapenem resistance in Escherichia coli by CRISPR-Cas9 system

CRISPR-Cas9-Mediated Carbapenemase Gene and Plasmid Curing in Carbapenem-Resistant Enterobacteriaceae

A Highly Efficient CRISPR-Cas9-Based Genome Engineering Platform in Acinetobacter Baumannii to Understand the H2O2-Sensing Mechanism of OxyR.

Reversal of mcr-1-Mediated Colistin Resistance in Escherichia coli by CRISPR-Cas9 System

Epidemiology and Molecular Characteristics of <i>mcr-9</i> in <i>Citrobacter</i> spp. from Healthy Individuals and Patients in China

Re-engineering a mobile-CRISPR/Cas9 system for antimicrobial resistance gene curing and immunization in <i>Escherichia coli</i>

A transposon-associated CRISPR/Cas9 system specifically eliminates both chromosomal and plasmid-borne mcr-1 in Escherichia coli

Engineering conjugative CRISPR-Cas9 systems for the targeted control of enteric pathogens and antibiotic resistance

Exploring the Potential of CRISPR-Cas9 Under Challenging Conditions: Facing High-Copy Plasmids and Counteracting Beta-Lactam Resistance in Clinical Strains of Enterobacteriaceae

Non-replicative phage particles delivering CRISPR-Cas9 to target major blaCTX-M variants

Efficient Suppression of Natural Plasmid-Borne Gene Expression in Carbapenem-Resistant Klebsiella pneumoniae Using a Compact CRISPR Interference System

Resensitizing tigecycline- and colistin-resistant Escherichia coli using an engineered conjugative CRISPR/Cas9 system

Application of CRISPR/Cas9-Based Genome Editing in Studying the Mechanism of Pandrug Resistance in Klebsiella pneumoniae

The Type I-E CRISPR-Cas System Influences the Acquisition of Blakpc-Incf Plasmid in Klebsiella Pneumonia

Transcription modulation of pathogenic streptococcal and enterococcal species using CRISPRi technology

Making point mutations in Escherichia coli BL21 genome using the CRISPR-Cas9 system

Improving the Editing Efficiency of CRISPR-Cas9 by Reducing the Generation of Escapers Based on the Surviving Mechanism

Exploiting a Conjugative Endogenous CRISPR-Cas3 System to Tackle Multidrug-Resistant Klebsiella Pneumoniae.

Sequence-Specific Removal of Shiga Toxin-Producing Escherichia Coli Using the Crispr-Cas9 System

Generation of Newly Discovered Resistance Gene mcr-1 Knockout in Escherichia coli Using the CRISPR/Cas9 System.

CRISPR-Cas3 and Type I Restriction-Modification Team Up Against Blakpc-Incf Plasmid Transfer in Klebsiella Pneumoniae